RHB Research Downgrades Hartalega to 'Sell' On Valuation

Why It Matters

The downgrade signals heightened risk for investors in the nitrile glove sector, where oversupply and raw‑material volatility could curb profit growth.

Key Takeaways

• RHB cuts Hartalega rating to Sell despite higher target price.
• Valuation outpaces fundamentals amid structural glove oversupply.
• Raw material disruptions and weak USD/Ringgit may pressure margins.
• Earnings forecasts lifted 2%‑62% for FY2026‑2028, ASPs up $7.

Pulse Analysis

The global nitrile glove market, which surged during the COVID‑19 pandemic, is now entering a period of correction. Demand has stabilized while production capacity, especially in China, continues to expand, creating a structural oversupply that squeezes prices. Malaysian manufacturers such as Hartalega, once benefitting from premium pricing, now face intense competition from lower‑cost Chinese peers that set market rates. At the same time, raw‑material inputs—primarily naphtha‑derived butadiene—are subject to geopolitical shocks, adding another layer of cost volatility to an already crowded field.

RHB Research’s decision to downgrade Hartalega to ‘Sell’ reflects these market pressures despite a modestly higher price target of RM1.01 (about $0.22). The brokerage argues that the recent share rally has detached from fundamentals, with valuation expansion unjustified given persistent oversupply and a weakening US dollar against the ringgit, which limits margin expansion. Although RHB projects temporary upside from lagged fuel‑cost benefits—fuel accounts for roughly 20 % of Hartalega’s cost of goods sold—it warns that any margin gains are likely short‑lived as input costs readjust.

For investors, the downgrade underscores the need to scrutinize earnings quality rather than price momentum. Hartalega’s earnings forecasts for FY2026‑2028 have been nudged upward, driven by assumptions of modest ASP growth of $7 per unit in early FY2027, but the upside is capped by price‑setting dynamics in China and potential feedstock disruptions. Portfolio managers may consider diversifying exposure across glove producers with stronger cost‑control or those expanding into higher‑margin medical devices. In the broader context, the sector’s recovery will hinge on balancing supply growth with sustainable demand, making valuation discipline essential.